Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: Consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology (非酒精性脂肪性肝病与相关代谢紊乱诊疗共识--中华医学会内分泌学分会肝病与代谢学组)

• Published in: Journal of diabetes 2013-12, Vol.5 (4), p.406-415
• Main Authors: Gao, Xin, Fan, Jian-Gao
• Format: Article
• Language: English
• Subjects: China; Consensus; diagnosis; Endocrinology - standards; Fatty Liver - complications; Fatty Liver - diagnosis; Fatty Liver - therapy; Humans; Liver; Liver - metabolism; Liver diseases; management; Metabolic Diseases - diagnosis; Metabolic Diseases - etiology; Metabolic Diseases - therapy; Metabolic disorders; Metabolism; Mortality; NAFLD; Non-alcoholic Fatty Liver Disease; Practice Guidelines as Topic; Review; Societies, Medical - standards; Society; 非酒精性脂肪性肝病，代谢紊乱，诊断，处理
• ISSN: 1753-0393; 1753-0407
• DOI: 10.1111/1753-0407.12056

Non‐alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries, affecting 20%–33% of the general population. Large population‐based surveys in China indicate a prevalence of approximately 15%–30%. Worldwide, including in China, the prevalence of NAFLD has increased rapidly in parallel with regional trends of obesity, type2 diabetes and metabolic syndrome. In addition, NAFLD has contributed significantly to increased overall, as well as cardiovascular and liver‐related, mortality in the general population. In view of rapid advances in research into NAFLD in recent years, this consensus statement provides a brief update on the progress in the field and suggests preferred approaches for the comprehensive management of NAFLD and its related metabolic diseases. 摘要 非酒精性脂肪性肝病（Non‐alcoholic fatty liver disease，NAFLD) 是西方国家最常见的肝脏疾病，在普通人群中的患病率约为20%–33%。我国已报道的研究数据显示，我国普通人群中NAFLD患病率已达到15%–30%。事实上NAFLD患病率在整个世界范围内迅速上升，并且与这些区域的肥胖、代谢综合征、2型糖尿病的患病率呈平行上升趋势。尤其重要的是，NAFLD增加普通人群的总体死亡率和心血管、肝病相关死亡率。近年来在NAFLD研究领域发展迅速，在复习近期国内外的研究进展的基础上，形成了我国内分泌学分会肝病与代谢学组“非酒精性脂肪性肝病与相关代谢紊乱诊疗共识”，旨在为内分泌代谢专业医生提供NAFLD诊疗相关的最新研究进展以及正确、规范处理NALFD和与之相关的代谢性疾病的方法。